Stabil KOAH hastalarında yaş, vücut kitle indeksi, tam kan sayımı ve biyokimyasal parametrelerin etkileri

Yıl 2021, , 7 - 11, 30.01.2021

Muhammed Emin , Aydın Balcı

https://doi.org/10.16899/jcm.829476

Öz

Amaç: Kronik obstrüktif akciğer hastalığı (KOAH) dünya çapında görülür ve esas olarak yaşlıları etkiler. KOAH'ı belirli çizgilerle tanımlamak genellikle imkansızdır ve çoğunlukla kılavuzlarla belirlenmiş tam bir tedavi prosedürü yoktur. GOLD kılavuzu, hastaları semptomlara ve eski alevlenme öyküsüne göre gruplandırmak için bölümsel bir KOAH değerlendirme yaklaşımı kullanır . Farklı patobiyolojik yolları yansıtan çeşitli biyobelirteçlerin eşzamanlı tespiti, artmış ölüm riski olan hastaların tanınmasına yardımcı olabilir Çalışmalar, obezitenin solunum mekaniği, kas rahatsızlığı ve nefes kontrolü nedeniyle genel popülasyonda azalmış akciğer fonksiyonuyla ilişkili olduğunu göstermiştir.
Gereç yöntem : Çalışmamıza ortalama yaşı 62,% 74'ü erkek olan 90 KOAH'lı hasta GOLD sınıflamasına göre A, B, C ve D olmak üzere dört gruba ayrıldı. Biyokimyasal parametreler, VKİ, yaş, cinsiyet ve hastalık şiddeti arasındaki ilişkiyi GOLD alt gruplarına göre araştırmak için analizler yapıldı..
Bulgular : KOAH Grup B'deki hastaların VKİ değerleri A grubuna göre daha yüksek iken, obezite ile KOAH şiddeti arasındaki ilişkiyi gösteren çalışmalarla uyumluydu; C ve D gruplarından yüksek olması obezite paradoksunu ortaya koyan çalışmalarla uyumluydu. Crp, Prokalsitonin, Sedimantasyon, Kalsiyum, Magnezyum seviyeleri ve diğer tam kan sayımı değerleri GOLD grupları arasında anlamlı bir fark göstermedi.
Sonuç: KOAH hastalarının genellikle 40 yaşın üzerinde olduğu ve yaşın hastalığın şiddeti ile bağlantılı olduğu önceki çalışmalarla tutarlı olduğu ortaya konulmuştur

Anahtar Kelimeler

Vücut kitle İndeksi, tam kan parametreleri, KOAH

Destekleyen Kurum

herhangi bir kurumdan destek alınmamıştır

Proje Numarası

proje kapsamında yapılmamıştır

Teşekkür

teşekkür edilecek kimse yoktur

Effects Of Age, Body Mass Index, Complete Blood Count Parameters, and Biochemical Parameters on Stable COPD Patients

Öz

Aim: Chronic obstructive pulmonary disease (COPD) is worldwide and mainly affects the elderly. It is often impossible to define COPD with specific lines, and it has no complete cure procedure, mostly established by guidelines. The GOLD guideline uses a sectional COPD evaluation approach to group patients by symptoms and former history of exacerbations. The concurrent detection of various biomarkers reflecting different pathobiological pathways might help recognize patients with an increased risk of death. Studies showed that obesity is related to decreased lung function in the general population due to respiratory mechanics, muscular discomfort, and breath control.
Material and Method: Ninety patients with COPD, whose mean age was 62, and 74% were male, were divided into four groups as A, B, C, and D according to the GOLD classification, were included in our study. Analyses were conducted to investigate the association between biochemical parameters, BMI, age, gender, and disease severity, according to GOLD subgroups.
Results: It has been demonstrated that COPD patients are generally over the age of 40 and age correlates with the severity of the disease consistent with previous studies. Our study has shown that COPD usually occurs over the age of 40, and there is a relationship between advanced age and the severity of COPD.
Conclusion: Our results are consistent with previous studies where COPD patients are usually over 40 years old, and age is linked to disease severity. While the BMI values of the patients in group B were higher than those of group A, it was compatible with studies showing the relationship between obesity and severity of COPD; being higher than C and D groups was consistent with the studies revealing the obesity paradox. Crp, Procalcitonin, Sedimentation, Calcium, Magnesium levels, and other complete blood count values showed no significant difference between GOLD groups.

Anahtar Kelimeler

body mass index, complete blood count parameters, COPD

Proje Numarası

proje kapsamında yapılmamıştır

Kaynakça

• 1. Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.
• 2. Zider AD, Wang X, Buhr RG, et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017 Sep;152(3):494-501.
• 3. Stolz D, Meyer A, Rakic J, et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur Respir J. 2014 Dec;44(6):1557-70.
• 4. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058–1067.
• 5. Agustı' A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
• 6. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161.
• 7. Kelly E, Owen CA, Pinto-Plata V, et al. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013; 7: 57–64.
• 8. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med 2015; 3: 435–442.
• 9. Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. J COPD F. 2015;2(1):23-34.
• 10. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004;59:574–580.
• 11. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.
• 12. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.
• 13. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: The evolving clinical challenge. Chest. 2012;141:396–405.
• 14. Lacoma A, Prat C, Andreo F, Domínguez J. Biomarkers in the management of COPD. Eur Respir Rev 2009;18(112):96–104. 15. Dahl M. Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. Am J Respir Crit Care Med 2008;177(11):1177–1178.
• 16. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7(8):e43892. doi:10.1371/journal.pone.0043892.
• 17. Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore). 2016;95(28):e4225. doi:10.1097/MD.0000000000004225.
• 18. Holm KE, Plaufcan MR, Ford DW, et al. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. J Behav Med. 2014;37(4):654-663. doi:10.1007/s10865-013-9516-7.
• 19. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741–50.
• 20. Corry-Anke Brandsma, Maaike de Vries, Rita Costa, Roy R. Woldhuis, Melanie Königshoff, Wim Timens. Lung ageing and COPD: is there a role for ageing in abnormal tissue repair? European Respiratory Review 2017 26: 170073; DOI: 10.1183/16000617.0073-2017.
• 21. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55.
• 22. World Health Organization. Overweight and obesity: a new nutrition emergency? Monitoring the rapidly emerging public health problem of overweight and obesity: the WHO global database on body mass index. SCN News 2004:5–12.
• 23. Jubber AS. Respiratory complications of obesity. Int J Clin Pract 2004;58:573–80.
• 24. Poulain M, Doucet M, Major GC, et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006;174:1293–9.
• 25. Cebron Lipovec N., Beijers R.J., van den Borst B., Doehner W., Lainscak M., Schols A.M. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD. 2016;13:399–406.
• 26. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. The American Journal of Clinical Nutrition. 2005;82:53–59.
• 27. Agapakis DI, Massa EV, Hantzis I et al. The role of mean platelet volume in chronic obstructive pulmonary disease exacerbation. Resp Care 2016; 61: 44-8.
• 28. Gallego M, Pomares X, Capilla S et al. C reactive protein in outpatients with acute exacerbation of COPD; its relationship with microbial etiology and severity. Int’l J COPD 2016; 11: 2633-40.
• 29. De Jager CPC, Paul TLV Wijk, Mathoera RB, Jongh- Leuvenink JD, Poll TVD, Wever PC. Lymphocytopenia and neutrophil- lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 2010; 14: R192.7.
• 30. Kocak MZ. Evaluation of red cell distribution width levels during acute exacerbation in patients with chronic obstructive pulmonary disease. Biomed Res India 2017; 28: 3009-11.8.
• 31. Karadeniz G, Aktogu S, Erer OF, Bulac Kir S, Doruk S, Demir M. Evaluation of mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease. Eur Resp J 2015; 46:3984-7.
• 32. Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:2721-2730. Published 2018 Sep 4. doi:10.2147/COPD.S170353